Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133981) titled 'Bispecific Antibodies Drive Improved Survival in Third-Line Therapy for RelapsedRefractory Diffuse Large B-Cell Lymphoma A Real-Word Study Before and After 2024' on Oct. 9.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: The First Affiliated Hospital of Soochow University
Condition:
Relapsed/refractory diffuse large B-cell lymphoma after failure of at least two lines of systemic therapy (third-line treatment population)
Intervention:
Previous Cohort (2020-2023 Cohort):None
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2025-08-31
Target Sample Siz...